Copyright © 2020 MarketWatch, Inc. All rights reserved. The analyst wrote in a recent note to clients that key clinical data readouts are coming up in the second half of 2020. The average price target stands tall at $8.13, which suggests room for almost 400% upside. Announces Pricing of $27.5 Million Public Offering of Common StockAquaBounty Technologies, Inc. PGEN | Complete Precigen Inc. stock news by MarketWatch. Germantown, MD 20876
This would provide women with the ability to remain protected without the inconvenience of needing to obtain another prescription if a patch is lost, unlike the case with Xulane.To sum it all up, Gershell said, “With an approved product that we project will achieve 2024E sales of ~$340 million, an enterprise value of just ~$210 million, and cash runway through 2021, we view AGRX as attractive.”Based on all of the above, it’s no wonder Gershell reiterated his Outperform call.
Given its $3.49 share price, some believe that now is the ideal time to get on board.Among PGEN’s fans are Englander and Millennium. Get the latest Precigen, Inc. (PGEN) stock news and headlines to help you in your trading and investing decisions.
As for the value of this new position, it comes in at $3,390,000.JMP analyst Jason Butler is also taking a bullish approach. With one already approved product, Twirla, that provides women with a contraceptive option that doesn’t require taking a daily pill or committing to a longer-lasting method, several members of the Street believe its $2.80 share price looks like a steal.Standing squarely in the bull camp, Englander just upped the ante. We want to hear from you.Sign up for free newsletters and get more CNBC delivered to your inboxGet this delivered to your inbox, and more info about our products and services. Stock analysis for Precigen Inc (PGEN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. While the onset of the pandemic extended the pre-launch period for Twirla, with the actual launch expected in Q4 2020, this isn’t necessarily a bad thing.“Extended pre-launch window of time appears to be to AGRX's benefit, allowing the company to curate sales professionals who bring skill sets well-adapted to both in-person communication as well as virtual engagement.
It is also destroyed automatically for you when the symbol is changed.To set your timezone use the location button below, or scroll through the following list...Got a confidential news tip? Real time Precigen, Inc. (PGEN) stock price quote, stock graph, news & analysis. Stock quote and company snapshot for PRECIGEN INC (PGEN), including profile, stock chart, recent news and events, analyst opinions, and research reports.
(See BiomX stock analysis on TipRanks)Agile Therapeutics (AGRX)Last but not least we have Agile Therapeutics, which focuses on addressing the unmet health needs of women. Despite patch category to be shared w/MYL's Xulane, we see Twirla's advantages (most importantly, low hormonal dose) as favorable to coverage prospects as well as prescriber/patient choice,” Gershell stated.Speaking to its commercialization plan, Gershell is especially interested to see if AGRX will offer a patch replacement program.
After 6 years, this nurse practitioner was told her public-service job did not qualify for student-debt forgiveness ]Precigen (PGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.Of all the controversial plays on Wall Street, penny stocks take the cake. (To watch Butler’s track record, click here) Turning now to the rest of the Street, it has been relatively quiet when it comes to other analyst activity.
(See Agile stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.He’s pinpointed 18 recommendations that went on to soar 1,000% or more. Stock market looks like ‘hapless Wile E. Coyote, running off the edge of a cliff,’ says behavioral economist GERMANTOWN, Md., June 11, 2020 Precigen (PGEN), Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen (PGEN), will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Forum on June 18, 2020, at 1:40 PM ET. Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies.